X0206 3 2020-06-25 0 0001722271 Akouos, Inc. AKUS 0001297709 Novartis Bioventures Ltd FORUM 1-1.32, LICHTSTRASSE 35 BASEL V8 CH-4056 SWITZERLAND 0 0 1 0 0001114448 NOVARTIS AG FORUM 1-1.32, LICHTSTRASSE 35 BASEL V8 CH-4056 SWITZERLAND 0 0 1 0 Series A Preferred Stock Common Stock 856262 I See Footnote Series B Preferred Stock Common Stock 199996 I See Footnote The Series A Preferred Stock is convertible into Common Stock on a 21.073-for-1 basis into the number of shares of Common Stock as shown in Column 3 without payment of further consideration, at any time at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date. Novartis Bioventures Ltd. is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities. The Series B Preferred Stock is convertible into Common Stock on a 21.073-for-1 basis into the number of shares of Common Stock as shown in Column 3 without payment of further consideration, at any time at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date. Exhibit 24.1 - Power of Attorney Novartis Bioventures Ltd., By: /s/ Bart Dzikowski, Title: Secretary of the Board, By: /s/ Beat Steffen, Title: Authorized Signatory 2020-06-25 Novartis AG, By: /s/ Bart Dzikowski, Title: Authorized Signatory, By: /s/ Beat Steffen, Title: Authorized Signatory 2020-06-25